Cyclerion Therapeutics, Inc. (CYCN): Price and Financial Metrics

Cyclerion Therapeutics, Inc. (CYCN): $2.82

-0.03 (-1.05%)

POWR Rating

Component Grades













Add CYCN to Watchlist
Sign Up

Industry: Biotech


of 491

in industry

CYCN Stock Summary

  • Cyclerion Therapeutics Inc's stock had its IPO on March 18, 2019, making it an older stock than just 4.22% of US equities in our set.
  • CYCN's price/sales ratio is 42.27; that's higher than the P/S ratio of 93.65% of US stocks.
  • Revenue growth over the past 12 months for Cyclerion Therapeutics Inc comes in at -49.06%, a number that bests only 6.3% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CYCN, based on their financial statements, market capitalization, and price volatility, are BLUE, MRKR, EVGN, TBPH, and APTX.
  • CYCN's SEC filings can be seen here. And to visit Cyclerion Therapeutics Inc's official web site, go to

CYCN Stock Price Chart Interactive Chart >

Price chart for CYCN

CYCN Price/Volume Stats

Current price $2.82 52-week high $8.96
Prev. close $2.85 52-week low $2.18
Day low $2.75 Volume 121,352
Day high $2.96 Avg. volume 661,636
50-day MA $3.82 Dividend yield N/A
200-day MA $4.29 Market Cap 96.04M

Cyclerion Therapeutics, Inc. (CYCN) Company Bio

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CYCN Latest News Stream

Event/Time News Detail
Loading, please wait...

CYCN Latest Social Stream

Loading social stream, please wait...

View Full CYCN Social Stream

Latest CYCN News From Around the Web

Below are the latest news stories about Cyclerion Therapeutics Inc that investors may wish to consider to help them evaluate CYCN as an investment opportunity.

TransMedics Appoints Stephanie Lovell to Board of Directors

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Stephanie Lovell to its Board of Directors and as a member of the Nominating and Corporate Governance Committee, effective March 22, 2021.

Yahoo | March 24, 2021

Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system (CNS), today announced that it will present a corporate overview at upcoming investor conferences: * 39th Annual J.P. Morgan Healthcare Conference. A presentation and Q&A discussion will take place on Thursday, January 14, 2021 at 3:40 p.m. ET and a live webcast may be accessed within the Investors & Media section of the website. An archived replay will be available for approximately 90 days following the presentation. * H.C. Wainwright BioConnect Conference. An on-demand presentation will be available on Monday January 11, 2021 at 6:00 a...

Yahoo | January 4, 2021

Andreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More Shares

Investors who take an interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) should definitely note that the Chief...

Yahoo | November 15, 2020

Cyclerion to Participate at Upcoming September 2020 Investor Conferences

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Company management will be participating in several upcoming September 2020 investor conferences: * Citi’s 15th Annual BioPharma Virtual Conference on September 9th * H.C. Wainwright & Co 22nd Annual Global Investment Conference on September 16th at 9:30 a.m. ET * Cantor Virtual Global Healthcare Conference on September 16th and a virtual Fireside Chat on September 17th at 3:20 p.m. ET * Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21st –23rd on September 21st at 10:50 a.m....

Yahoo | September 4, 2020

Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program

CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today announced that it has been awarded a grant from the Alzheimer's Association’s Part the Cloud-Gates Partnership Grant Program. This award will support the Company’s upcoming Phase 2 trial of IW-6463 in Alzheimer’s Disease with vascular pathology (ADv). The award provides Cyclerion with $2 million of funding over the next 2 years. “We are very pleased to have won this highly competitive award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program. Human genetic evidence and preclinical data suggest that stimulation of soluble guanylate cyclase (sGC) with IW-6463 can...

Yahoo | August 25, 2020

Read More 'CYCN' Stories Here

CYCN Price Returns

1-mo -33.96%
3-mo -15.82%
6-mo -15.82%
1-year N/A
3-year N/A
5-year N/A
YTD -7.84%
2020 12.50%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9491 seconds.